Ensitrelvir, a new anti-COVID drug, marks a milestone against future betacoronaviruses
Ensitrelvir, an oral anti-COVID-19 drug, has been granted full authorization in Japan and shown to effectively prevent symptomatic COVID-19 infection post-exposure, reducing incidence by 67%. Developed by Shionogi, it targets the SARS-CoV-2 main protease (Mpro) using computational chemistry, avoiding the issues of Pfizer's Nirmatrelvir (Paxlovid). This drug represents a significant milestone beyond COVID-19, as it targets a protein common to betacoronaviruses, a sub-family responsible for SARS-CoV-1, MERS-CoV, and SARS-CoV-2. Its success provides scientists with a valuable starting point for rapidly developing drugs against future viral outbreaks.
Key Points
- Ensitrelvir, an oral anti-COVID-19 drug, has received full authorization in Japan.
- Clinical trials (SCORPIO-PEP) showed Ensitrelvir reduced symptomatic COVID-19 incidence by 67% post-exposure.
- The drug targets the SARS-CoV-2 main protease (Mpro), a key enzyme for viral replication.
- Ensitrelvir's success is a milestone for developing broad-spectrum antivirals against betacoronaviruses, which include SARS-CoV-1, MERS-CoV, and SARS-CoV-2.
- The drug was developed by Shionogi using computational chemistry, offering advantages over Pfizer's Nirmatrelvir.
Exam Facts
- Drug name: Ensitrelvir.
- Target: SARS-CoV-2 main protease (Mpro).
- Developer: Shionogi (Japanese pharmaceutical company).
- Trial name: SCORPIO-PEP trial (involved 2,387 participants).
- Virus sub-family: Betacoronaviruses (SARS-CoV-1, MERS-CoV, SARS-CoV-2).
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.